References
- Cancer Incidence in Five Continents Vol. 8. International Agency for Research on Cancer Web site. http://www-dep.iarc.fr/CI5_original/ table2.asp?cancer=170&volume=8&sex=1&age_from=1&age_to=18& submit=Execute. html. Updated May 2007. Accessed August 15, 2007
- Jadvar H, Gamie S, Ramanna L, Conti PS. Musculoskeletal system. Semin Nucl Med 2004;34:254-261 https://doi.org/10.1053/j.semnuclmed.2004.06.002
- Schwarzbach M, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. ANN Surg 2000;231:380-6 https://doi.org/10.1097/00000658-200003000-00011
-
Watanabe H, Shinozaki T, Yanagawa T, Aoki J, Tokunaga M, Inoue T, et al. Glucose metabolic analysis of musculoskeletal tumours using
$^{18}$ fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000;82:760-7 https://doi.org/10.1302/0301-620X.82B5.9824 - Schwarzbach M, Hinz U, Strauss LG, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. ANN Surg 2005;241:286-94 https://doi.org/10.1097/01.sla.0000152663.61348.6f
- Griffeeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro - 2 - deoxy - D - glucose. Radiology 1992;182: 185-94 https://doi.org/10.1148/radiology.182.1.1727280
- Folpe AL, Lyles RH, Sprouse JT, ConradIII EU, Eary JF. (F-18) Florodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;287:1279-87
-
Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative
$^{18}$ F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510-8 - Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F] fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33: 683-91 https://doi.org/10.1007/s00259-005-0044-8
- Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR, et al. FDG-PET for evaluation musculoskeletal tumors. J Orthop Sci 2003;8:435-41 https://doi.org/10.1007/s10776-001-0539-6
- Aoki J , Watanabe H, Shinozaki T, Takagishi K, Ishihima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors : standard uptake value of 52 lesions. Radiology 2001;219:774-7 https://doi.org/10.1148/radiology.219.3.r01ma08774
- Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18 fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998;39:810-5
- Eary J, Conard EU. PET imaging : Update on sarcomas. Oncology 2007;21:249-52
- Gilkey FW, Moser RP. The biology of cartilage. ed. Philadelphia: Hanley and Belfus; 1990. p. 1-7
- Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K et al. Diagnostic accuracy of bone metastases detection in cancer patients : comparison between bone scintigraphy and whole body FDG-PET. Ann Nucl Med 2006;20:399-408 https://doi.org/10.1007/BF03027375
- Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W et al. The value of FDG -PET in the detection, grading and response to therapy of soft tissue and bone sarcoma; a systematic review and meta- analysis. cancer treatmemt reviews 2004;30:83-101 https://doi.org/10.1016/j.ctrv.2003.07.004
- Schulte M, Brecht -Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41:1695-701
- Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trsk DD, McGuire AH, et al. Benign versus Malignant Intraosseous Lesions : Discrimination by Means of PET with 2- [F-18] fluoro-2-deoxy- D-glucose. Radiology 1996;200:243-7 https://doi.org/10.1148/radiology.200.1.8657920
- Ioannidis JPA, Lau J. 18F- FDG PET for the Diagnosis and Grading of Soft Tissue sarcoma: A Meta-Analysis. J Nucl Med 2003;44:717-24
- Lee SM. Nodular fasciitis mimicking malignant tumor in F-18 FDG PET/CT. Korean J Nucl Med 2005;39:263-5
- Ogose A, Hotta T, Morita T, Yamammura S, Hosaka N, Kobayashi H, et al. Tumors of peripheral nerves: correlation of symptom, clinical signs, imaging features, and histologic diagnosis. Skeletal Radiol 1999;28:183-8 https://doi.org/10.1007/s002560050498
- Magnani P, Thomas TP, Tennekon G, De Vries GH, Greene DA, Brosiu FC III. Regulation of glucose transport in cultured Schwann cells. J Peripheral nerve Syst 1998;25:589-92
- Hamada K, Ueda T, Higuchi I, Inoue A, Tamai N, Myoi A, et al. Peripheral nerve schwannoma: two cases exhibiting increased FDG uptake inearly and delayed PET imaging. Skeletal Radiol 2005; 34:52-7 https://doi.org/10.1007/s00256-004-0845-z
- Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K. Schwannoma of the extremities: the role of PET in preoperative planning. Eur J Nucl Med 2001;28:1541-51 https://doi.org/10.1007/s002590100584
- Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, et al. Evaluation of 18-fluorodeoxyglucose positron emission tomography (18FDG-PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis. J Neurol Neurosurg Psychiatry 2000;68:353-7 https://doi.org/10.1136/jnnp.68.3.353
- Gyorke T, Zajic T, Lange A, Schafer O, Moser E, Mako E, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 2006;27:17-24 https://doi.org/10.1097/01.mnm.0000186608.12895.69
- Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU, et al. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors. J Clin Oncol 2005;23:8828-34 https://doi.org/10.1200/JCO.2005.01.7079
- Johnston J. Giant cell tumor of bone: the role of the giant cell in orthopedic pathology. Orthop Clin North Am 1977;8:751-70
- Ling L, Klein MJ, Sissons HA, Steiner GC, Winchester RJ. Expression of Ia and monocyte and macrophages lineage antigens in giant cell tumor of bone and related lesions. Arch Pathol Lab Med 1988;112:65-9
- Vinay Kumar, Abul K. Abbas, Nelson Fausto. Robbins and Cotran Pathologic basis of disease 7th ed. Philadelphia, Pa. : Elsevier Saunders, 2005;p1273-324
- Dahlin DC, Unni KK Bone tumors:general aspects and data on 8542 cases. 4th ed. Springfield: Thomas; 1986. p. 413-20
- Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue (editorial). J Nucl Med 1993;34:419-21
- Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. Bone 2001;28:21-8 https://doi.org/10.1016/S8756-3282(00)00426-9
- Raisz LG, Rodan GA, Cellular basis for bone turn over. In: Avioli LV, Krane SM, eds. Metabolic bone disease and clinically related disorders. 2nd ed. Philadephia: Saunders; 1990. P. 1-41
- Chae HL, Park YH. F-18 FDG uptake in the nidus of an osteoid osteoma. Clin nucl med 2007;32:628-30 https://doi.org/10.1097/RLU.0b013e3180a1acf3